UTv Videos

Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men.

Aleece Fosnight, MSPAS, PA-C, argues that incontinence must be understood as a common, treatable medical condition rather than a personal failure or an inevitable part of aging.

Fed Ghali, MD, discusses the potential opportunity to de-escalate therapy in patients receiving perioperative EV/pembro.

Gal Wald, MD, highlights patient-reported outcomes from a phase 2 trial of intravesical gemcitabine plus BCG for patients with BCG-exposed high-grade NMIBC.

Another critical research need involves understanding the effects of exogenous testosterone.

Sameena A. Rahman, MD, said she anticipates that the regulatory stance may encourage more clinicians to adopt a layered therapeutic approach for patients with severe GSM.

Lin Lin, MD, highlights a phase 2 trial of neoadjuvant SAbR followed by surgery in patients with newly diagnosed renal cell carcinoma and caval tumor thrombus.

Eugene Pietzak, MD, highlights the background and design of the ongoing phase 3 GAIN trial, exploring the combination of gemcitabine and BCG in BCG-exposed NMIBC.

The primary end point is overall survival, with secondary end points including PSA response metrics, progression measures, PSA kinetics, and several ctDNA assessments to help identify which patients benefit most.

Siamak Daneshmand, MD, emphasizes that, at present, optimal patient selection remains unclear because resistance mechanisms and predictive biomarkers are not yet well understood.

Mark D. Tyson, II, MD, MPH, recapped topline results from the BOND-003 trial of cretostimogene grenadenorepvec in papillary only BCG-unresponsive NMIBC.

For patients undergoing salvage surgery or radiation, Kelly L. Stratton, MD, FACS, notes that previous focal therapy can influence outcomes.

TULSA patients were treated and discharged the same day.

Laura Bukavina, MD, MPH, offered her thoughts on the significance of the KEYNOTE-905 data and highlighted some remaining questions surrounding the regimen.

Stratton emphasized that the trial’s results provide greater confidence in recommending therapy and allow clinicians to counsel patients more decisively about next steps when PSA begins to rise.

Michael S. Cookson, MD, MMHC, FACS, shares his thoughts on the most exciting recent advances in bladder cancer treatment.

Joshua J. Meeks, MD, PhD, discussed the emerging role of ctDNA in guiding adjuvant and neoadjuvant strategies in patients with bladder cancer.

Laser technology is expected to play a major role in the next wave of innovation.

Learn how suction has become central to contemporary ureteroscopic practice and how its integration is reshaping surgical decision-making, treatment algorithms, and the perceived role of percutaneous procedures.

Karen L. Stern, MD, and Naeem Bhojani, MD, FRCSC, outline the advantages of CVAC 2.0, particularly in cases involving larger stone burdens.

Experts compare and contrast direct in-scope suction with the flexible and navigable ureteric access sheath.

In this opening segment, the discussion focuses on the rapid evolution of kidney stone surgery and how suction has transitioned from an aspirational idea to a core component of modern ureteroscopy.

Cameron J. Britton, MD, highlights key findings from a study of the MyProstateScore 2.0 in predicting upgrading to GG≥3 prostate cancer.

Roger Li, MD, discusses the development and validation of a CHAI-based biomarker to identify patients with LG NMIBC who are at higher risk of progression.

INVITE is a 2-part clinical trial designed to evaluate the safety, feasibility, and patient experience of administering intravesical bladder cancer therapies in the home.

One notable trend is the shift of therapies originally reserved for heavily pretreated, castration-resistant prostate cancer into earlier phases of disease.

The ENLIGHTED trial is evaluating the safety and efficacy of padeliporfin vascular targeted photodynamic therapy for low-grade upper tract urothelial carcinoma.